Compared to all different types of breast cancers, human epidermal growth factor receptor 2 (HER2), overexpressing (HER2+) and triple-negative breast cancers (TNBC, estrogen/progesterone receptors negative (ER/PR-) and HER2-) are more likely to develop the metastatic disease due to their aggressive tumor characteristics [1,2,3,4]. This evidence concerns the gene ERBB2 and neoplasm.